Dabomb Protein Biotech's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 39.75.
Dabomb Protein Biotech's Days Inventory for the
three
months ended in Dec. 2025 was 32.51.
Dabomb Protein Biotech's Days Payable for the
three
months ended in Dec. 2025 was 20.93.
Therefore, Dabomb Protein Biotech's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 51.33.
Dabomb Protein Biotech (ROCO:6578) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Dabomb Protein Biotech Cash Conversion Cycle Related Terms
Dabomb Protein Biotech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Dabomb Protein Biotech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech Cash Conversion Cycle Chart
ROCO:6578 vs KHC, GIS: Cash Conversion Cycle Comparison
For the Packaged Foods subindustry, Dabomb Protein Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech Cash Conversion Cycle vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's Cash Conversion Cycle falls into.
Dabomb Protein Biotech Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Dabomb Protein Biotech's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a Cash Conversion Cycle of 51.33 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Dabomb Protein Biotech and its competitors.
Is Dabomb Protein Biotech's Cash Conversion Cycle too high?
Dabomb Protein Biotech's current Cash Conversion Cycle is 51.33. The Consumer Packaged Goods industry median Cash Conversion Cycle is 75.52. Dabomb Protein Biotech's value of 51.33 is 32% below this industry median. Overall, Dabomb Protein Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Cash Conversion Cycle compare to KHC and GIS?
Dabomb Protein Biotech's Cash Conversion Cycle of 51.33 can be compared against companies in the Consumer Packaged Goods industry. The industry median Cash Conversion Cycle is 75.52. Dabomb Protein Biotech's value of 51.33 is 32% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Consumer Packaged Goods company?
The median Cash Conversion Cycle among Consumer Packaged Goods companies is 75.52, based on 1,941 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current Cash Conversion Cycle of 51.33 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median Cash Conversion Cycle is 75.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current Cash Conversion Cycle is 51.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.52, compared to a current price of NT$16.40 — trading 12.9% above its estimated fair value. The current Cash Conversion Cycle is 51.33 and 32% below the Consumer Packaged Goods industry median of 75.52. Dabomb Protein Biotech's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Cash Conversion Cycle is 51.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$16.40 is trading 12.9% above its estimated GF Value™ of NT$14.52.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
Cash Conversion Cycle: 51.33
GF Value™: NT$14.52 vs. price of NT$16.40 (12.9% above fair value)
Industry Position: 32% below the Consumer Packaged Goods median
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
59GF Score
Get the complete analysis for ROCO:6578
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
